REVVITY, INC.

Life Sciences

Revenue for the three months ended June 29, 2025 was $365.9 million, as compared to $348.5 million for the three months ended June 30, 2024, an increase of $17.4 million, or 5%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue during the three months ended June 29, 2025 was driven by an increase of $17.1 million in Software revenue and an increase of $0.3 million in Life Sciences Solutions revenue.

Revenue for the six months ended June 29, 2025 was $706.3 million, as compared to $685.0 million for the six months ended June 30, 2024, an increase of $21.3 million, or 3%. The increase in our Life Sciences segment revenue during the six months ended June 29, 2025 was driven by an increase of $26.1 million in Software revenue, partially offset by a decrease of $4.9 million in Life Sciences Solutions revenue.

Segment operating income for the three months ended June 29, 2025 was $115.5 million, as compared to $117.6 million for the three months ended June 30, 2024, a decrease of $2.1 million, or 2%. Segment operating margin decreased 218 basis points in the three months ended June 29, 2025, as compared to the three months ended June 30, 2024, primarily due to increased tariffs and product mix shift partially offset by higher productivity.

Segment operating income for the six months ended June 29, 2025 was $221.2 million, as compared to $218.5 million for the six months ended June 30, 2024, an increase of $2.7 million, or 1%. Segment operating margin decreased 58 basis points in the six months ended June 29, 2025, as compared to the six months ended June 30, 2024, primarily due to increased tariffs, product mix shift, and continued investments in new product development and digital capabilities.

Diagnostics

Revenue for the three months ended June 29, 2025 was $354.4 million, as compared to $343.2 million for the three months ended June 30, 2024, an increase of $11.2 million, or 3%, which includes an approximate 1% increase in revenue attributable to favorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended June 29, 2025 was driven by an increase of $5.6 million in Immunodiagnostics revenue andan increase of $5.7 million in Reproductive Health revenue.

Revenue for the six months ended June 29, 2025 was $678.8 million, as compared to $656.6 million for the six months ended June 30, 2024, an increase of $22.2 million, or 3%. Theincrease in our Diagnostics segment revenue duringthe six months ended June 29, 2025 was driven by an increase of $14.5 million in Immunodiagnostics revenue andan increase of $7.7 million in Reproductive Health revenue.

Segment operating incomefor the three months ended June 29, 2025 was $89.4 million, as compared to $92.7 millionfor the three months ended June 30, 2024, a decrease of $3.3 million, or 4%. Segment operating margin decreased 179 basis points in the three months ended June 29, 2025, as compared to the three months ended June 30, 2024, primarily due to increased tariffs, product mix shift, unfavorable changes in foreign exchange rates, and continued investments in new product development and digital capabilities partially offset by pricing actions.

Segment operating incomefor the six months ended June 29, 2025 was $163.4 million, as compared to $169.0 millionfor the six months ended June 30, 2024, a decrease of $5.5 million, or 3%. Segment operating margin decreased 165 basis points in the six months ended June 29, 2025, as compared to the six months ended June 30, 2024, primarily due to increased tariffs, product mix shift, unfavorable changes in foreign exchange rates, and continued investments in new product development and digital capabilities partially offset by pricing actions.